top of page

"Every year, millions of individuals face life-threatening allergic reactions, with many unable to access timely and effective treatment... the limitations of current adrenaline delivery systems pose challenges in terms of accessibility, ease of use, and rapid administration, especially in emergency situations."

- AdraCard CEO, Liam Mahony, suffers from anaphylaxis

Anaphylaxis Factors

Patient truths

146 Million patients suffer from Anaphylaxis

60% of patients don't carry daily

"I didn't think I would need it today" - most common response when questioned in the Emergency Department 

 30-45% of those who do carry chose not to inject due to needle phobia

Current solutions are  invasive and expensive 

Current solutions aren't tolerant to harsh temperatures  

Image by CDC

"Patient First" Tech

By identifying the true patient-needs early in the development process, our innovative 'Patient First' technologies are specifically tailored for the end user. Currently, these needs are not being adequately addressed...

Meet the Team

Our team is committed to bringing innovative solutions to market. We are guided by a distinguished panel of advisors, including leading physicians, commercialisation experts, and industry veterans who bring invaluable insights and expertise to our project.

Proudly supported by  


Find out more

Thanks for your interest!

bottom of page